Detail akcie Acrivon Therape Rg online

Business Summary: Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Acrivon Therapeutics Inc revenues was not reported. Net loss increased 15% to $40.7M. Higher net loss reflects Research and development of oncology therapies segment loss increase of 13% to $44.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.25 to -$1.06.